Current Research Studies

AGCT1532: A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors)

AGCT1532

Condition(s): Germ Cell Tumors, Newly diagnosed, Other, Recurrent and/or Refractory, Solid Tumor, Survivorship
Phase: III
Clinicaltrials.gov ID: NCT02582697

What is the goal of the study?

The overall goal of this study is to determine whether accelerated BEP will be effective and well-tolerated for patients with advanced germ cell tumors. We don't yet know if accelerated treatment is helpful in advanced germ cell tumors and we are hoping this study will answer that question.

Who can participate in the study?

This study may be a good fit for indidivuals with an intermediate and poorrisk metastatic germ cell tumor. For details about study eligibility, read more about this study on clinicaltrials.gov.

Study Team:

PI (Study Doctor): Tyler Ketterl
Study Team Member: HemOnc CRAs, [email protected]